ABSTRACT BACKGROUND For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if b-blockers are
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STATISTICAL ANALYSIS. Baseline characteristics according to treatment with b-blockers were described by using number and percentage for categorical data and mean AE SD or median and interquartile range for normally and non-normally distributed continuous data, respectively. Differences in characteristics were assessed by using chi-square tests, 2-sample Student t tests, and, for non-normally distributed data, the Mann-Whitney U test. Adjusted Kaplan-Meier curves were used to assess survival differences between patients who received b-blockers and those who did not.
Survival time inverse probability weighting propensity score analysis (13, 14) was used to evaluate the association between b-blocker use and mortality by estimating the average treatment effects (ATEs) and ATEs on the treated. Briefly, the method incorporated 2 models, the first of which was a treatment assignment model that estimated the propensity for b-blocker treatment assignment and was used to derive inverse probability weights. This model Other discharge diagnosis 55,981
Strengthening A Poisson regression analysis with an offset for the log survival time between discharge and final follow-up was used to provide a better approximation of the survival modeling framework. Analyses were undertaken for the overall AMI cohort and separately for cases of STEMI and NSTEMI, and effects were investigated at 1 month, 6 months, and 1 year.
To mitigate potential bias caused by missing data, we used multiple imputation by chained equations to create 10 datasets from 20 iterations; the resultant model estimates for each were combined by using Rubin's rules (Online Appendix, Online Table 2 ).
There was also no significant treatment effect for the use of b-blockers at 1 month, 6 months, and 1 year for STEMI and NSTEMI. b-blocker use, most of the included studies pre-dated the introduction of invasive coronary treatments (19) .
A meta-analysis of 10 observational studies across >40,000 patients suggested a lack of evidence to support the routine use of b-blockers in all patients
with AMI who received PCI, but the effect was Values are mean AE SD, n (%), or median (interquartile range). *Total number of patients with missing information for b-blocker use at hospital discharge: 31,496. †Peak troponin level was truncated at 50 ng/ml. ‡Of the eligible patients for the care intervention. §Proportion missing of the eligible patients for the care intervention. kTotal eligible for care intervention. In an era of coronary revascularization for AMI, whether it is primary PCI for acute STEMI or a risk-dependent early invasive strategy for NSTEMI, the likelihood of preserving more viable and therefore less arrhythmogenic myocardium is potentially greater than that of the noninterventional era. .9
.8
. cation for all patients with AMI who do not have a contraindication (7, 8) .
STUDY LIMITATIONS. Even though, to our knowledge, this study was the largest analysis to date (comprising >180,000 cases) of the effectiveness of b-blockers on mortality after AMI without HF or LVSD, our study was not without limitations. Only patients who survived the hospital stay were studied and, consequently, the role of in-hospital b-blockers was not investigated (e.g., for patients with early arrhythmias complicating AMI). The presence of HF or LVSD was only assessed by using data recorded during the hospital stay, and the risk of developing HF in the year after AMI, while declining, is not small (16, 17) . In such circumstances, there is good evidence that b-blockers are beneficial and associated with lower mortality rates and better cardiovascular outcomes (22) .
In addition, there was no information in the present study about rates of discontinuation, new prescriptions, or doses of b-blockers after hospital discharge. It is possible that nonpersistence with *The average treatment effects (ATEs) represent the absolute difference in survival time (months, respective to the follow-up time category) between b-blocker treatment versus no treatment across the whole cohort (comparing survival times in a scenario in which all patients were treated versus survival times in a scenario in which no patients were treated). †The average treatment effects on the treated (ATET) represent the absolute difference in survival time between b-blocker treatment versus no b-blocker treatment estimated only among those who were treated (comparing survival times for all b-blocker patients versus the potential survival time in the scenario that the treated patients did not receive b-blockers).
AMI ¼ acute myocardial infarction; CI ¼ confidence interval; other abbreviations as in Table 1 . Abbreviations as in Tables 1 and 2 . In this study, patients experiencing an acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction were commonly prescribed b-blockers at hospital discharge (94.8%). However, in this nationwide observational study using propensity score analysis (1-year follow-up), the use of b-blockers
was not associated with a significant difference in survival times after AMI. Dondo et al. 
